Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 911-919

  Samudio, Ismael J ^a   Duvvuri, Seshagiri ^a   Clise Dwyer, Karen ^a   Watt, Julie C ^a   Mak, Duncan ^a   Kantarjian, Hagop ^a   Yang, Dajun ^b   Ruvolo, Vivian ^a   Borthakur, Gautam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ascenta Therapeutics   (United States)

Author keywords

Acute myelogenoid leukemia; MDM2; MI 63; P53

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DOXORUBICIN; MI 63; PROTEIN MDMX; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; FLOW CYTOMETRY; G1 PHASE; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77951823170     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003731325     Document Type: Article

References (26)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
3. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459.
4. Pinyol M, Hernandez L, Martinez A, et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000;156:1987-1996.
5. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006;13:927-934.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83.
7. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
9. Kubbutat MH, Ludwig RL, Levine AJ, Vousden KH. Analysis of the degradation function of Mdm2. Cell Growth Differ 1999;10:87-92.
10. Nie L, Sasaki M, Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 2007;282:14616-14625.
11. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
12. Herzog G, Lu-Hesselmann J, Zimmermann Y, Haferlach T, Hiddemann W, Dreyling M. Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events. Haematologica 2005;90:693-695.
13. Faderl S, Kantarjian HM, Estey E, et al. The prognostic significance of p16 (INK4a)/p14 (ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000;89:1976-1982.
14. Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma 1995;17:13-18.
15. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-2623.
16. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000.
17. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-3159.
18. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584-1593.
19. Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008;7:1533-1542.
20. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006;49:3432-3435.
21. Rasola A, Geuna M. A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry 2001;45:151-157.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
23. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-3176.
24. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008;7:1604-1612.
25. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008;105:3933-3938.
26. Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008;7:2427-2433.